The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with Tazobactam resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Cobicistat resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Darunavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with tranylcypromine resulting in a loss in efficacy.


The serum concentration of the active metabolites of primidone can be reduced when primidone is used in combination with Levomefolic acid resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with cimetidine resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Telithromycin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Levonorgestrel resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with diltiazem resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with RUCAPARIB resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with indinavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with itraconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with RIFABUTIN resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Cobicistat resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Retigabine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Quinine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Panobinostat resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Idelalisib resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with indinavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with nevirapine resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with TICARCILLIN resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with amiodarone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telaprevir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Norelgestromin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Atazanavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Isavuconazonium resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with fluoxetine resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Conivaptan resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with buprenorphine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with carbamazepine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with pilocarpine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with RIFAPENTINE resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Posaconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with amoxicillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with imipramine resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with Dothiepin resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with penicillin g resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with clofibrate resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with gemfibrozil resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with isoniazid resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with oxacillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with phenytoin resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with paroxetine resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with bupropion resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with dexlansoprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of prednisone can be reduced when prednisone is used in combination with Tesamorelin resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with amiodarone resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with ropinirole resulting in a loss in efficacy.


The serum concentration of the active metabolites of nelfinavir can be reduced when nelfinavir is used in combination with lansoprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with Flucloxacillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with ketoconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with Penicillin G benzathine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with primidone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with nevirapine resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with erythromycin resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with clotrimazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with clomipramine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with desipramine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Rolapitant resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with primidone resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with PENICILLIN G PROCAINE resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with Pivmecillinam resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with moclobemide resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with betaxolol resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with NORGESTIMATE resulting in a loss in efficacy.


The serum concentration of the active metabolites of albendazole can be reduced when albendazole is used in combination with phenytoin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Voriconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telithromycin resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with isoniazid resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with ketoconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with dexlansoprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with cyclosporin A resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with tranylcypromine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with clemastine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with ETONOGESTREL resulting in a loss in efficacy.


The serum concentration of the active metabolites of tegafur can be reduced when tegafur is used in combination with amiodarone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with ketoconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Telaprevir resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Artemether resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with ELIGLUSTAT resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with paroxetine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of albendazole can be reduced when albendazole is used in combination with carbamazepine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with methimazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with nicardipine resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with sulfisoxazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of nelfinavir can be reduced when nelfinavir is used in combination with dexlansoprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with sertraline resulting in a loss in efficacy.


The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with RIFABUTIN resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with nelfinavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with miconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of nelfinavir can be reduced when nelfinavir is used in combination with nevirapine resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with topiramate resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with clarithromycin resulting in a loss in efficacy.


The serum concentration of the active metabolites of OXCARBAZEPINE can be reduced when OXCARBAZEPINE is used in combination with phenytoin resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with ticlopidine resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with Armodafinil resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with ranitidine resulting in a loss in efficacy.


The serum concentration of the active metabolites of OXCARBAZEPINE can be reduced when OXCARBAZEPINE is used in combination with Fosphenytoin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with nevirapine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Abiraterone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Lumacaftor resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with quinidine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with chloroquine resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with SULBACTAM resulting in a loss in efficacy.


The serum concentration of the active metabolites of nelfinavir can be reduced when nelfinavir is used in combination with rabeprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with nevirapine resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Bortezomib resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with lansoprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with MEZLOCILLIN resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Boceprevir resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Boceprevir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with diethylstilbestrol resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with phenytoin resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with Pivampicillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with SAQUINAVIR resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with rabeprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of tegafur can be reduced when tegafur is used in combination with clotrimazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with AMPHETAMINE resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with efavirenz resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with clozapine resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with Luliconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Nilotinib resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Lopinavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with lovastatin resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with pantoprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Atazanavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with promazine resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with dihydroergotamine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with phenobarbital resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Mirabegron resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Dexfenfluramine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with phenobarbital resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with tranylcypromine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with duloxetine resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with ticlopidine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with celecoxib resulting in a loss in efficacy.


The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with RIFAPENTINE resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with dexamethasone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Telithromycin resulting in a loss in efficacy.


The serum concentration of the active metabolites of nelfinavir can be reduced when nelfinavir is used in combination with omeprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with indinavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Drospirenone resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with nicardipine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with rosiglitazone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with letrozole resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Vitamin D3 resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with phenobarbital resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with menadione resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with fluoxetine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with manidipine resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with nafcillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with rabeprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with SAQUINAVIR resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with piperacillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with norgestrel resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with azlocillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with chloramphenicol resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Nilotinib resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with Zucapsaicin resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with VERAPAMIL resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with diphenhydramine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Boceprevir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Lumacaftor resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with memantine resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with sertraline resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Cobicistat resulting in a loss in efficacy.


The serum concentration of the active metabolites of nelfinavir can be reduced when nelfinavir is used in combination with Esomeprazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with clemastine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with indinavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with ritonavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with azelastine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with carbamazepine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with clarithromycin resulting in a loss in efficacy.


The serum concentration of the active metabolites of tegafur can be reduced when tegafur is used in combination with nicotine resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with Abiraterone resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Atomoxetine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifampicin resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with fluconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of buprenorphine can be reduced when buprenorphine is used in combination with efavirenz resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with nilvadipine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with metyrapone resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with cimetidine resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with methadone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Rifampicin resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with itraconazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with Lobeglitazone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Idelalisib resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with venlafaxine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with sulfaphenazole resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with amiodarone resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with cloxacillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with Atazanavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Darunavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with citalopram resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with nefazodone resulting in a loss in efficacy.


The serum concentration of the active metabolites of HYDROCODONE can be reduced when HYDROCODONE is used in combination with terbinafine resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with azithromycin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with nevirapine resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with penicillin v resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Fosphenytoin resulting in a loss in efficacy.


The serum concentration of the active metabolites of Imatinib can be reduced when Imatinib is used in combination with gemfibrozil resulting in a loss in efficacy.


The serum concentration of the active metabolites of ifosfamide can be reduced when ifosfamide is used in combination with doxycycline resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with ampicillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with modafinil resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with norfloxacin resulting in a loss in efficacy.


The serum concentration of the active metabolites of NORGESTIMATE can be reduced when NORGESTIMATE is used in combination with efavirenz resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Dronedarone resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Ziprasidone resulting in a loss in efficacy.


The serum concentration of the active metabolites of albendazole can be reduced when albendazole is used in combination with phenobarbital resulting in a loss in efficacy.


The serum concentration of the active metabolites of mycophenolic acid can be reduced when mycophenolic acid is used in combination with dicloxacillin resulting in a loss in efficacy.


The serum concentration of the active metabolites of tamoxifen can be reduced when tamoxifen is used in combination with Cobicistat resulting in a loss in efficacy.


The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with amiodarone resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with SAQUINAVIR resulting in a loss in efficacy.


The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.


The serum concentration of the active metabolites of clopidogrel can be reduced when clopidogrel is used in combination with Vitamin D3 resulting in a loss in efficacy.


phenindione may decrease the anticoagulant activities of estradiol.


phenindione may decrease the anticoagulant activities of propylthiouracil.


warfarin may decrease the anticoagulant activities of Norelgestromin.


dicumarol may decrease the anticoagulant activities of methimazole.


warfarin may decrease the anticoagulant activities of potassium iodide.


dicumarol may decrease the anticoagulant activities of nafcillin.


dicumarol may decrease the anticoagulant activities of potassium iodide.


PHENPROCOUMON may decrease the anticoagulant activities of Dienogest.


dicumarol may decrease the anticoagulant activities of Medroxyprogesterone acetate.


phenindione may decrease the anticoagulant activities of NORGESTIMATE.


phenindione may decrease the anticoagulant activities of norgestrel.


phenindione may decrease the anticoagulant activities of Carbimazole.


ACENOCOUMAROL may decrease the anticoagulant activities of azathioprine.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of estradiol.


warfarin may decrease the anticoagulant activities of estramustine.


warfarin may decrease the anticoagulant activities of ETHYNODIOL DIACETATE.


warfarin may decrease the anticoagulant activities of mestranol.


pentosan polysulfate may decrease the anticoagulant activities of ethinyl estradiol.


phenindione may decrease the anticoagulant activities of Drospirenone.


PHENPROCOUMON may decrease the anticoagulant activities of phytonadione.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of estrone.


phenindione may decrease the anticoagulant activities of dienestrol.


argatroban may decrease the anticoagulant activities of estrone.


citric acid may decrease the anticoagulant activities of ethinyl estradiol.


ACENOCOUMAROL may decrease the anticoagulant activities of Dienogest.


Rivaroxaban may decrease the anticoagulant activities of estrone.


citric acid may decrease the anticoagulant activities of QUINESTROL.


phenindione may decrease the anticoagulant activities of diethylstilbestrol.


phenindione may decrease the anticoagulant activities of estrone.


EDTA may decrease the anticoagulant activities of estriol.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of QUINESTROL.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of estriol.


dicumarol may decrease the anticoagulant activities of Norelgestromin.


citric acid may decrease the anticoagulant activities of estriol.


warfarin may decrease the anticoagulant activities of nafcillin.


PHENPROCOUMON may decrease the anticoagulant activities of NORGESTIMATE.


warfarin may decrease the anticoagulant activities of Medroxyprogesterone acetate.


phenindione may decrease the anticoagulant activities of cloxacillin.


EDTA may decrease the anticoagulant activities of dienestrol.


PHENPROCOUMON may decrease the anticoagulant activities of Carbimazole.


argatroban may decrease the anticoagulant activities of QUINESTROL.


dicumarol may decrease the anticoagulant activities of Dienogest.


argatroban may decrease the anticoagulant activities of estriol.


EDOXABAN may decrease the anticoagulant activities of QUINESTROL.


dicumarol may decrease the anticoagulant activities of 6-Mercaptopurine.


PHENPROCOUMON may decrease the anticoagulant activities of Drospirenone.


citric acid may decrease the anticoagulant activities of mestranol.


PHENPROCOUMON may decrease the anticoagulant activities of dienestrol.


warfarin may decrease the anticoagulant activities of estriol.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of estradiol.


phenindione may decrease the anticoagulant activities of Flucloxacillin.


EDTA may decrease the anticoagulant activities of diethylstilbestrol.


dicumarol may decrease the anticoagulant activities of ETONOGESTREL.


phenindione may decrease the anticoagulant activities of DESOGESTREL.


warfarin may decrease the anticoagulant activities of phytonadione.


phenindione may decrease the anticoagulant activities of potassium iodide.


PHENPROCOUMON may decrease the anticoagulant activities of diethylstilbestrol.


phenindione may decrease the anticoagulant activities of Norelgestromin.


PHENPROCOUMON may decrease the anticoagulant activities of estrone.


warfarin may decrease the anticoagulant activities of Levonorgestrel.


warfarin may decrease the anticoagulant activities of Sucralfate.


ACENOCOUMAROL may decrease the anticoagulant activities of ethinyl estradiol.


dicumarol may decrease the anticoagulant activities of GESTODENE.


pentosan polysulfate may decrease the anticoagulant activities of diethylstilbestrol.


PHENPROCOUMON may decrease the anticoagulant activities of propylthiouracil.


phenindione may decrease the anticoagulant activities of dicloxacillin.


ACENOCOUMAROL may decrease the anticoagulant activities of dicloxacillin.


PHENPROCOUMON may decrease the anticoagulant activities of Sucralfate.


dicumarol may decrease the anticoagulant activities of cloxacillin.


ACENOCOUMAROL may decrease the anticoagulant activities of Levonorgestrel.


ACENOCOUMAROL may decrease the anticoagulant activities of Sucralfate.


dicumarol may decrease the anticoagulant activities of Drospirenone.


dicumarol may decrease the anticoagulant activities of ETHYNODIOL DIACETATE.


warfarin may decrease the anticoagulant activities of QUINESTROL.


dicumarol may decrease the anticoagulant activities of phytonadione.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of QUINESTROL.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of estriol.


phenindione may decrease the anticoagulant activities of phytonadione.


ACENOCOUMAROL may decrease the anticoagulant activities of methimazole.


PHENPROCOUMON may decrease the anticoagulant activities of Flucloxacillin.


pentosan polysulfate may decrease the anticoagulant activities of estrone.


warfarin may decrease the anticoagulant activities of cloxacillin.


PHENPROCOUMON may decrease the anticoagulant activities of potassium iodide.


PHENPROCOUMON may decrease the anticoagulant activities of Norelgestromin.


warfarin may decrease the anticoagulant activities of diethylstilbestrol.


phenindione may decrease the anticoagulant activities of mestranol.


ACENOCOUMAROL may decrease the anticoagulant activities of Carbimazole.


Bivalirudin may decrease the anticoagulant activities of estrone.


phenindione may decrease the anticoagulant activities of ETHYNODIOL DIACETATE.


Dabigatran etexilate may decrease the anticoagulant activities of QUINESTROL.


Apixaban may decrease the anticoagulant activities of estrone.


PHENPROCOUMON may decrease the anticoagulant activities of dicloxacillin.


dicumarol may decrease the anticoagulant activities of Coenzyme Q10.


EDTA may decrease the anticoagulant activities of estradiol.


Rivaroxaban may decrease the anticoagulant activities of estriol.


Rivaroxaban may decrease the anticoagulant activities of QUINESTROL.


ACENOCOUMAROL may decrease the anticoagulant activities of diethylstilbestrol.


PHENPROCOUMON may decrease the anticoagulant activities of cloxacillin.


PHENPROCOUMON may decrease the anticoagulant activities of norgestrel.


phenindione may decrease the anticoagulant activities of 6-Mercaptopurine.


phenindione may decrease the anticoagulant activities of Dienogest.


phenindione may decrease the anticoagulant activities of Estrone sulfate.


warfarin may decrease the anticoagulant activities of Carbimazole.


phenindione may decrease the anticoagulant activities of Coenzyme Q10.


warfarin may decrease the anticoagulant activities of NORGESTIMATE.


Fondaparinux may decrease the anticoagulant activities of mestranol.


warfarin may decrease the anticoagulant activities of azathioprine.


Ximelagatran may decrease the anticoagulant activities of estrone.


Fondaparinux may decrease the anticoagulant activities of QUINESTROL.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of mestranol.


phenindione may decrease the anticoagulant activities of QUINESTROL.


citric acid may decrease the anticoagulant activities of estrone.


Fondaparinux may decrease the anticoagulant activities of estrone.


PHENPROCOUMON may decrease the anticoagulant activities of mestranol.


warfarin may decrease the anticoagulant activities of Flucloxacillin.


EDTA may decrease the anticoagulant activities of QUINESTROL.


phenindione may decrease the anticoagulant activities of estramustine.


warfarin may decrease the anticoagulant activities of DESOGESTREL.


warfarin may decrease the anticoagulant activities of Drospirenone.


citric acid may decrease the anticoagulant activities of estradiol.


ACENOCOUMAROL may decrease the anticoagulant activities of Drospirenone.


PHENPROCOUMON may decrease the anticoagulant activities of ETHYNODIOL DIACETATE.


dicumarol may decrease the anticoagulant activities of propylthiouracil.


ACENOCOUMAROL may decrease the anticoagulant activities of NORGESTIMATE.


warfarin may decrease the anticoagulant activities of estradiol.


dicumarol may decrease the anticoagulant activities of dicloxacillin.


dicumarol may decrease the anticoagulant activities of diethylstilbestrol.


PHENPROCOUMON may decrease the anticoagulant activities of DESOGESTREL.


ACENOCOUMAROL may decrease the anticoagulant activities of dienestrol.


Fondaparinux may decrease the anticoagulant activities of estriol.


pentosan polysulfate may decrease the anticoagulant activities of estriol.


ACENOCOUMAROL may decrease the anticoagulant activities of Flucloxacillin.


phenindione may decrease the anticoagulant activities of estriol.


ACENOCOUMAROL may decrease the anticoagulant activities of DESOGESTREL.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of mestranol.


pentosan polysulfate may decrease the anticoagulant activities of QUINESTROL.


ACENOCOUMAROL may decrease the anticoagulant activities of GESTODENE.


PHENPROCOUMON may decrease the anticoagulant activities of 6-Mercaptopurine.


ACENOCOUMAROL may decrease the anticoagulant activities of propylthiouracil.


ACENOCOUMAROL may decrease the anticoagulant activities of estradiol.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of ethinyl estradiol.


ACENOCOUMAROL may decrease the anticoagulant activities of estrone.


phenindione may decrease the anticoagulant activities of azathioprine.


ACENOCOUMAROL may decrease the anticoagulant activities of ETHYNODIOL DIACETATE.


phenindione may decrease the anticoagulant activities of ETONOGESTREL.


dicumarol may decrease the anticoagulant activities of Flucloxacillin.


PHENPROCOUMON may decrease the anticoagulant activities of estramustine.


ACENOCOUMAROL may decrease the anticoagulant activities of cloxacillin.


dicumarol may decrease the anticoagulant activities of dienestrol.


PHENPROCOUMON may decrease the anticoagulant activities of Coenzyme Q10.


phenindione may decrease the anticoagulant activities of Medroxyprogesterone acetate.


dicumarol may decrease the anticoagulant activities of norgestrel.


Apixaban may decrease the anticoagulant activities of QUINESTROL.


Apixaban may decrease the anticoagulant activities of estriol.


phenindione may decrease the anticoagulant activities of nafcillin.


dicumarol may decrease the anticoagulant activities of NORGESTIMATE.


warfarin may decrease the anticoagulant activities of norgestrel.


PHENPROCOUMON may decrease the anticoagulant activities of estriol.


PHENPROCOUMON may decrease the anticoagulant activities of Estrone sulfate.


PHENPROCOUMON may decrease the anticoagulant activities of QUINESTROL.


warfarin may decrease the anticoagulant activities of ethinyl estradiol.


citric acid may decrease the anticoagulant activities of diethylstilbestrol.


EDTA may decrease the anticoagulant activities of estrone.


Bivalirudin may decrease the anticoagulant activities of QUINESTROL.


PHENPROCOUMON may decrease the anticoagulant activities of azathioprine.


warfarin may decrease the anticoagulant activities of dicloxacillin.


Fondaparinux may decrease the anticoagulant activities of ethinyl estradiol.


warfarin may decrease the anticoagulant activities of propylthiouracil.


warfarin may decrease the anticoagulant activities of dienestrol.


phenindione may decrease the anticoagulant activities of GESTODENE.


ACENOCOUMAROL may decrease the anticoagulant activities of ETONOGESTREL.


pentosan polysulfate may decrease the anticoagulant activities of estradiol.


phenindione may decrease the anticoagulant activities of Sucralfate.


phenindione may decrease the anticoagulant activities of Levonorgestrel.


PHENPROCOUMON may decrease the anticoagulant activities of ETONOGESTREL.


ACENOCOUMAROL may decrease the anticoagulant activities of norgestrel.


phenindione may decrease the anticoagulant activities of methimazole.


EDOXABAN may decrease the anticoagulant activities of estriol.


warfarin may decrease the anticoagulant activities of trazodone.


ACENOCOUMAROL may decrease the anticoagulant activities of QUINESTROL.


ACENOCOUMAROL may decrease the anticoagulant activities of Estrone sulfate.


ACENOCOUMAROL may decrease the anticoagulant activities of estriol.


Fondaparinux may decrease the anticoagulant activities of diethylstilbestrol.


warfarin may decrease the anticoagulant activities of methimazole.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of dienestrol.


PHENPROCOUMON may decrease the anticoagulant activities of estradiol.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of ethinyl estradiol.


warfarin may decrease the anticoagulant activities of Dienogest.


citric acid may decrease the anticoagulant activities of dienestrol.


phenindione may decrease the anticoagulant activities of ethinyl estradiol.


Ximelagatran may decrease the anticoagulant activities of estriol.


dicumarol may decrease the anticoagulant activities of DESOGESTREL.


Ximelagatran may decrease the anticoagulant activities of QUINESTROL.


ACENOCOUMAROL may decrease the anticoagulant activities of 6-Mercaptopurine.


PHENPROCOUMON may decrease the anticoagulant activities of GESTODENE.


ACENOCOUMAROL may decrease the anticoagulant activities of Norelgestromin.


ACENOCOUMAROL may decrease the anticoagulant activities of potassium iodide.


dicumarol may decrease the anticoagulant activities of estriol.


dicumarol may decrease the anticoagulant activities of azathioprine.


Fondaparinux may decrease the anticoagulant activities of estradiol.


warfarin may decrease the anticoagulant activities of GESTODENE.


ACENOCOUMAROL may decrease the anticoagulant activities of Coenzyme Q10.


Fondaparinux may decrease the anticoagulant activities of dienestrol.


dicumarol may decrease the anticoagulant activities of Carbimazole.


warfarin may decrease the anticoagulant activities of 6-Mercaptopurine.


ACENOCOUMAROL may decrease the anticoagulant activities of estramustine.


EDTA may decrease the anticoagulant activities of mestranol.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of diethylstilbestrol.


PHENPROCOUMON may decrease the anticoagulant activities of Levonorgestrel.


pentosan polysulfate may decrease the anticoagulant activities of dienestrol.


ACENOCOUMAROL may decrease the anticoagulant activities of mestranol.


PHENPROCOUMON may decrease the anticoagulant activities of methimazole.


dicumarol may decrease the anticoagulant activities of estrone.


PHENPROCOUMON may decrease the anticoagulant activities of nafcillin.


dicumarol may decrease the anticoagulant activities of estramustine.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of estrone.


PHENPROCOUMON may decrease the anticoagulant activities of Medroxyprogesterone acetate.


pentosan polysulfate may decrease the anticoagulant activities of mestranol.


dicumarol may decrease the anticoagulant activities of Sucralfate.


dicumarol may decrease the anticoagulant activities of estradiol.


dicumarol may decrease the anticoagulant activities of Levonorgestrel.


PHENPROCOUMON may decrease the anticoagulant activities of ethinyl estradiol.


ACENOCOUMAROL may decrease the anticoagulant activities of phytonadione.


dicumarol may decrease the anticoagulant activities of mestranol.


warfarin may decrease the anticoagulant activities of ETONOGESTREL.


3,4-Dihydroxybenzaldehyde may decrease the anticoagulant activities of dienestrol.


Bivalirudin may decrease the anticoagulant activities of estriol.


dicumarol may decrease the anticoagulant activities of ethinyl estradiol.


ACENOCOUMAROL may decrease the anticoagulant activities of nafcillin.


dicumarol may decrease the anticoagulant activities of QUINESTROL.


dicumarol may decrease the anticoagulant activities of Estrone sulfate.


ACENOCOUMAROL may decrease the anticoagulant activities of Medroxyprogesterone acetate.


EDTA may decrease the anticoagulant activities of ethinyl estradiol.


EDOXABAN may decrease the anticoagulant activities of estrone.


PENTAERYTHRITOL TETRANITRATE may decrease the anticoagulant activities of diethylstilbestrol.


The absorption of progesterone can be decreased when combined with CICLOPIROX.


The absorption of progesterone can be decreased when combined with Micafungin.


The absorption of progesterone can be decreased when combined with tolnaftate.


The absorption of progesterone can be decreased when combined with Caspofungin.


The absorption of progesterone can be decreased when combined with THYMOL.


The absorption of progesterone can be decreased when combined with Tavaborole.


The absorption of progesterone can be decreased when combined with Miltefosine.


The absorption of progesterone can be decreased when combined with Isoconazole.


The absorption of progesterone can be decreased when combined with sulconazole.


The absorption of progesterone can be decreased when combined with salicylic acid.


The absorption of progesterone can be decreased when combined with Artemether.


The absorption of progesterone can be decreased when combined with haloprogin.


The absorption of progesterone can be decreased when combined with 5-Fluorocytosine.


The absorption of progesterone can be decreased when combined with Anidulafungin.


The absorption of progesterone can be decreased when combined with chloroxine.


The absorption of progesterone can be decreased when combined with trimetrexate.


The absorption of progesterone can be decreased when combined with miconazole.


The absorption of progesterone can be decreased when combined with fluconazole.


The absorption of progesterone can be decreased when combined with NATAMYCIN.


The absorption of progesterone can be decreased when combined with amphotericin b.


The absorption of progesterone can be decreased when combined with nystatin.


The absorption of progesterone can be decreased when combined with EFINACONAZOLE.


The absorption of progesterone can be decreased when combined with tioconazole.


The absorption of progesterone can be decreased when combined with terbinafine.


The absorption of progesterone can be decreased when combined with terconazole.


The absorption of progesterone can be decreased when combined with itraconazole.


The absorption of progesterone can be decreased when combined with benzoic acid.


The absorption of progesterone can be decreased when combined with bifonazole.


The absorption of progesterone can be decreased when combined with rapamycin.


The absorption of progesterone can be decreased when combined with Sertaconazole.


The absorption of progesterone can be decreased when combined with cyclosporin A.


The absorption of progesterone can be decreased when combined with cerulenin.


The absorption of progesterone can be decreased when combined with Voriconazole.


The absorption of progesterone can be decreased when combined with hexetidine.


The absorption of progesterone can be decreased when combined with Posaconazole.


The absorption of progesterone can be decreased when combined with clotrimazole.


The absorption of progesterone can be decreased when combined with butenafine.


The absorption of progesterone can be decreased when combined with Butoconazole.


The absorption of progesterone can be decreased when combined with Naftifine.


The absorption of progesterone can be decreased when combined with oxiconazole.


The absorption of progesterone can be decreased when combined with pentamidine.


The absorption of progesterone can be decreased when combined with griseofulvin.


The absorption of progesterone can be decreased when combined with ketoconazole.


alprenolol may decrease the bronchodilatory activities of isoetharine.


BISOPROLOL may decrease the bronchodilatory activities of Indacaterol.


atenolol may decrease the bronchodilatory activities of terbutaline.


betaxolol may decrease the bronchodilatory activities of aminophylline.


alprenolol may decrease the bronchodilatory activities of aminophylline.


betaxolol may decrease the bronchodilatory activities of ritodrine.


BUPRANOLOL may decrease the bronchodilatory activities of PROCATEROL.


alprenolol may decrease the bronchodilatory activities of metaproterenol.


celiprolol may decrease the bronchodilatory activities of Bambuterol.


celiprolol may decrease the bronchodilatory activities of clenbuterol.


oxprenolol may decrease the bronchodilatory activities of Indacaterol.


oxprenolol may decrease the bronchodilatory activities of dobutamine.


betaxolol may decrease the bronchodilatory activities of metaproterenol.


penbutolol may decrease the bronchodilatory activities of formoterol.


penbutolol may decrease the bronchodilatory activities of ARBUTAMINE.


celiprolol may decrease the bronchodilatory activities of Arformoterol.


metoprolol may decrease the bronchodilatory activities of Salmeterol.


BUPRANOLOL may decrease the bronchodilatory activities of isoproterenol.


oxprenolol may decrease the bronchodilatory activities of Levalbuterol.


atenolol may decrease the bronchodilatory activities of PIRBUTEROL.


oxprenolol may decrease the bronchodilatory activities of PIRBUTEROL.


celiprolol may decrease the bronchodilatory activities of terbutaline.


metoprolol may decrease the bronchodilatory activities of dobutamine.


BOPINDOLOL may decrease the bronchodilatory activities of Arformoterol.


Nebivolol may decrease the bronchodilatory activities of celiprolol.


betaxolol may decrease the bronchodilatory activities of PROCATEROL.


betaxolol may decrease the bronchodilatory activities of clenbuterol.


betaxolol may decrease the bronchodilatory activities of Bambuterol.


BISOPROLOL may decrease the bronchodilatory activities of celiprolol.


penbutolol may decrease the bronchodilatory activities of PIRBUTEROL.


oxprenolol may decrease the bronchodilatory activities of clenbuterol.


BOPINDOLOL may decrease the bronchodilatory activities of Salmeterol.


acebutolol may decrease the bronchodilatory activities of isoproterenol.


BUPRANOLOL may decrease the bronchodilatory activities of ritodrine.


acebutolol may decrease the bronchodilatory activities of isoetharine.


oxprenolol may decrease the bronchodilatory activities of Salmeterol.


ESMOLOL may decrease the bronchodilatory activities of Indacaterol.


CARTEOLOL may decrease the bronchodilatory activities of Levalbuterol.


timolol may decrease the bronchodilatory activities of Indacaterol.


BOPINDOLOL may decrease the bronchodilatory activities of Salbutamol.


timolol may decrease the bronchodilatory activities of Salbutamol.


penbutolol may decrease the bronchodilatory activities of Vilanterol.


penbutolol may decrease the bronchodilatory activities of OLODATEROL.


atenolol may decrease the bronchodilatory activities of Vilanterol.


atenolol may decrease the bronchodilatory activities of OLODATEROL.


Nebivolol may decrease the bronchodilatory activities of PIRBUTEROL.


atenolol may decrease the bronchodilatory activities of theophylline.


oxprenolol may decrease the bronchodilatory activities of aminophylline.


atenolol may decrease the bronchodilatory activities of formoterol.


alprenolol may decrease the bronchodilatory activities of ritodrine.


alprenolol may decrease the bronchodilatory activities of formoterol.


oxprenolol may decrease the bronchodilatory activities of dyphylline.


timolol may decrease the bronchodilatory activities of OLODATEROL.


timolol may decrease the bronchodilatory activities of Vilanterol.


timolol may decrease the bronchodilatory activities of Levalbuterol.


atenolol may decrease the bronchodilatory activities of dyphylline.


BOPINDOLOL may decrease the bronchodilatory activities of dobutamine.


alprenolol may decrease the bronchodilatory activities of Bambuterol.


betaxolol may decrease the bronchodilatory activities of Salbutamol.


alprenolol may decrease the bronchodilatory activities of clenbuterol.


timolol may decrease the bronchodilatory activities of ritodrine.


timolol may decrease the bronchodilatory activities of formoterol.


celiprolol may decrease the bronchodilatory activities of Salmeterol.


BISOPROLOL may decrease the bronchodilatory activities of terbutaline.


celiprolol may decrease the bronchodilatory activities of aminophylline.


acebutolol may decrease the bronchodilatory activities of dyphylline.


ESMOLOL may decrease the bronchodilatory activities of ritodrine.


atenolol may decrease the bronchodilatory activities of phenylpropanolamine.


Nebivolol may decrease the bronchodilatory activities of theophylline.


CARTEOLOL may decrease the bronchodilatory activities of isoproterenol.


BUPRANOLOL may decrease the bronchodilatory activities of Levalbuterol.


BOPINDOLOL may decrease the bronchodilatory activities of Indacaterol.


timolol may decrease the bronchodilatory activities of dobutamine.


oxprenolol may decrease the bronchodilatory activities of theophylline.


acebutolol may decrease the bronchodilatory activities of terbutaline.


acebutolol may decrease the bronchodilatory activities of Bambuterol.


Nebivolol may decrease the bronchodilatory activities of terbutaline.


Nebivolol may decrease the bronchodilatory activities of dyphylline.


acebutolol may decrease the bronchodilatory activities of clenbuterol.


acebutolol may decrease the bronchodilatory activities of theophylline.


atenolol may decrease the bronchodilatory activities of ritodrine.


timolol may decrease the bronchodilatory activities of Salmeterol.


timolol may decrease the bronchodilatory activities of PIRBUTEROL.


BISOPROLOL may decrease the bronchodilatory activities of PIRBUTEROL.


BUPRANOLOL may decrease the bronchodilatory activities of Salmeterol.


BUPRANOLOL may decrease the bronchodilatory activities of clenbuterol.


BUPRANOLOL may decrease the bronchodilatory activities of Bambuterol.


BUPRANOLOL may decrease the bronchodilatory activities of Indacaterol.


BUPRANOLOL may decrease the bronchodilatory activities of Arformoterol.


acebutolol may decrease the bronchodilatory activities of Arformoterol.


betaxolol may decrease the bronchodilatory activities of Salmeterol.


ESMOLOL may decrease the bronchodilatory activities of isoetharine.


celiprolol may decrease the bronchodilatory activities of Salbutamol.


celiprolol may decrease the bronchodilatory activities of PROCATEROL.


atenolol may decrease the bronchodilatory activities of isoetharine.


CARTEOLOL may decrease the bronchodilatory activities of Indacaterol.


betaxolol may decrease the bronchodilatory activities of Indacaterol.


atenolol may decrease the bronchodilatory activities of metaproterenol.


timolol may decrease the bronchodilatory activities of aminophylline.


alprenolol may decrease the bronchodilatory activities of PROCATEROL.


BUPRANOLOL may decrease the bronchodilatory activities of phenylpropanolamine.


atenolol may decrease the bronchodilatory activities of isoproterenol.


atenolol may decrease the bronchodilatory activities of ARBUTAMINE.


metoprolol may decrease the bronchodilatory activities of Indacaterol.


metoprolol may decrease the bronchodilatory activities of Salbutamol.


BUPRANOLOL may decrease the bronchodilatory activities of formoterol.


celiprolol may decrease the bronchodilatory activities of phenylpropanolamine.


BOPINDOLOL may decrease the bronchodilatory activities of celiprolol.


celiprolol may decrease the bronchodilatory activities of dobutamine.


BISOPROLOL may decrease the bronchodilatory activities of Vilanterol.


BISOPROLOL may decrease the bronchodilatory activities of OLODATEROL.


penbutolol may decrease the bronchodilatory activities of isoproterenol.


timolol may decrease the bronchodilatory activities of dyphylline.


penbutolol may decrease the bronchodilatory activities of isoetharine.


alprenolol may decrease the bronchodilatory activities of isoproterenol.


BISOPROLOL may decrease the bronchodilatory activities of theophylline.


atenolol may decrease the bronchodilatory activities of clenbuterol.


BISOPROLOL may decrease the bronchodilatory activities of formoterol.


atenolol may decrease the bronchodilatory activities of Bambuterol.


BUPRANOLOL may decrease the bronchodilatory activities of Salbutamol.


acebutolol may decrease the bronchodilatory activities of Salmeterol.


Nebivolol may decrease the bronchodilatory activities of isoetharine.


BUPRANOLOL may decrease the bronchodilatory activities of terbutaline.


acebutolol may decrease the bronchodilatory activities of aminophylline.


ESMOLOL may decrease the bronchodilatory activities of Bambuterol.


oxprenolol may decrease the bronchodilatory activities of phenylpropanolamine.


CARTEOLOL may decrease the bronchodilatory activities of clenbuterol.


BISOPROLOL may decrease the bronchodilatory activities of dyphylline.


ESMOLOL may decrease the bronchodilatory activities of isoproterenol.


CARTEOLOL may decrease the bronchodilatory activities of Bambuterol.


atenolol may decrease the bronchodilatory activities of Levalbuterol.


Nebivolol may decrease the bronchodilatory activities of isoproterenol.


timolol may decrease the bronchodilatory activities of clenbuterol.


Nebivolol may decrease the bronchodilatory activities of ARBUTAMINE.


timolol may decrease the bronchodilatory activities of Bambuterol.


BUPRANOLOL may decrease the bronchodilatory activities of OLODATEROL.


BUPRANOLOL may decrease the bronchodilatory activities of Vilanterol.


ESMOLOL may decrease the bronchodilatory activities of Arformoterol.


oxprenolol may decrease the bronchodilatory activities of Salbutamol.


ESMOLOL may decrease the bronchodilatory activities of dyphylline.


metoprolol may decrease the bronchodilatory activities of aminophylline.


oxprenolol may decrease the bronchodilatory activities of metaproterenol.


CARTEOLOL may decrease the bronchodilatory activities of Arformoterol.


CARTEOLOL may decrease the bronchodilatory activities of dyphylline.


ESMOLOL may decrease the bronchodilatory activities of clenbuterol.


timolol may decrease the bronchodilatory activities of theophylline.


betaxolol may decrease the bronchodilatory activities of dobutamine.


BISOPROLOL may decrease the bronchodilatory activities of phenylpropanolamine.


Nebivolol may decrease the bronchodilatory activities of PROCATEROL.


alprenolol may decrease the bronchodilatory activities of terbutaline.


ESMOLOL may decrease the bronchodilatory activities of phenylpropanolamine.


Nebivolol may decrease the bronchodilatory activities of clenbuterol.


CARTEOLOL may decrease the bronchodilatory activities of ritodrine.


Nebivolol may decrease the bronchodilatory activities of Bambuterol.


BUPRANOLOL may decrease the bronchodilatory activities of aminophylline.


atenolol may decrease the bronchodilatory activities of aminophylline.


ESMOLOL may decrease the bronchodilatory activities of theophylline.


BOPINDOLOL may decrease the bronchodilatory activities of terbutaline.


oxprenolol may decrease the bronchodilatory activities of ritodrine.


BUPRANOLOL may decrease the bronchodilatory activities of dyphylline.


metoprolol may decrease the bronchodilatory activities of PIRBUTEROL.


oxprenolol may decrease the bronchodilatory activities of PROCATEROL.


penbutolol may decrease the bronchodilatory activities of dyphylline.


timolol may decrease the bronchodilatory activities of Arformoterol.


acebutolol may decrease the bronchodilatory activities of PROCATEROL.


metoprolol may decrease the bronchodilatory activities of metaproterenol.


BISOPROLOL may decrease the bronchodilatory activities of ritodrine.


CARTEOLOL may decrease the bronchodilatory activities of isoetharine.


timolol may decrease the bronchodilatory activities of terbutaline.


ESMOLOL may decrease the bronchodilatory activities of terbutaline.


oxprenolol may decrease the bronchodilatory activities of Bambuterol.


penbutolol may decrease the bronchodilatory activities of terbutaline.


ESMOLOL may decrease the bronchodilatory activities of PIRBUTEROL.


CARTEOLOL may decrease the bronchodilatory activities of terbutaline.


penbutolol may decrease the bronchodilatory activities of Bambuterol.


celiprolol may decrease the bronchodilatory activities of metaproterenol.


penbutolol may decrease the bronchodilatory activities of clenbuterol.


CARTEOLOL may decrease the bronchodilatory activities of PIRBUTEROL.


Nebivolol may decrease the bronchodilatory activities of metaproterenol.


Nebivolol may decrease the bronchodilatory activities of phenylpropanolamine.


alprenolol may decrease the bronchodilatory activities of PIRBUTEROL.


penbutolol may decrease the bronchodilatory activities of theophylline.


BISOPROLOL may decrease the bronchodilatory activities of isoetharine.


BOPINDOLOL may decrease the bronchodilatory activities of PIRBUTEROL.


BISOPROLOL may decrease the bronchodilatory activities of metaproterenol.


acebutolol may decrease the bronchodilatory activities of dobutamine.


Nebivolol may decrease the bronchodilatory activities of aminophylline.


oxprenolol may decrease the bronchodilatory activities of ARBUTAMINE.


acebutolol may decrease the bronchodilatory activities of Indacaterol.


alprenolol may decrease the bronchodilatory activities of ARBUTAMINE.


Nebivolol may decrease the bronchodilatory activities of ritodrine.


oxprenolol may decrease the bronchodilatory activities of isoproterenol.


penbutolol may decrease the bronchodilatory activities of Arformoterol.


penbutolol may decrease the bronchodilatory activities of ritodrine.


acebutolol may decrease the bronchodilatory activities of Salbutamol.


BISOPROLOL may decrease the bronchodilatory activities of isoproterenol.


betaxolol may decrease the bronchodilatory activities of celiprolol.


penbutolol may decrease the bronchodilatory activities of Levalbuterol.


BUPRANOLOL may decrease the bronchodilatory activities of dobutamine.


BISOPROLOL may decrease the bronchodilatory activities of ARBUTAMINE.


alprenolol may decrease the bronchodilatory activities of theophylline.


celiprolol may decrease the bronchodilatory activities of Levalbuterol.


metoprolol may decrease the bronchodilatory activities of isoetharine.


metoprolol may decrease the bronchodilatory activities of OLODATEROL.


metoprolol may decrease the bronchodilatory activities of Vilanterol.


alprenolol may decrease the bronchodilatory activities of Salmeterol.


metoprolol may decrease the bronchodilatory activities of dyphylline.


CARTEOLOL may decrease the bronchodilatory activities of phenylpropanolamine.


Nebivolol may decrease the bronchodilatory activities of formoterol.


atenolol may decrease the bronchodilatory activities of PROCATEROL.


ESMOLOL may decrease the bronchodilatory activities of formoterol.


BISOPROLOL may decrease the bronchodilatory activities of PROCATEROL.


ESMOLOL may decrease the bronchodilatory activities of aminophylline.


BISOPROLOL may decrease the bronchodilatory activities of clenbuterol.


BISOPROLOL may decrease the bronchodilatory activities of Bambuterol.


CARTEOLOL may decrease the bronchodilatory activities of aminophylline.


oxprenolol may decrease the bronchodilatory activities of formoterol.


ESMOLOL may decrease the bronchodilatory activities of Salmeterol.


alprenolol may decrease the bronchodilatory activities of Arformoterol.


timolol may decrease the bronchodilatory activities of isoetharine.


BUPRANOLOL may decrease the bronchodilatory activities of isoetharine.


BOPINDOLOL may decrease the bronchodilatory activities of Vilanterol.


alprenolol may decrease the bronchodilatory activities of dobutamine.


BOPINDOLOL may decrease the bronchodilatory activities of OLODATEROL.


celiprolol may decrease the bronchodilatory activities of PIRBUTEROL.


BOPINDOLOL may decrease the bronchodilatory activities of theophylline.


atenolol may decrease the bronchodilatory activities of Arformoterol.


celiprolol may decrease the bronchodilatory activities of formoterol.


celiprolol may decrease the bronchodilatory activities of ARBUTAMINE.


BOPINDOLOL may decrease the bronchodilatory activities of formoterol.


metoprolol may decrease the bronchodilatory activities of Bambuterol.


BISOPROLOL may decrease the bronchodilatory activities of Levalbuterol.


CARTEOLOL may decrease the bronchodilatory activities of formoterol.


CARTEOLOL may decrease the bronchodilatory activities of Salmeterol.


penbutolol may decrease the bronchodilatory activities of Salmeterol.


atenolol may decrease the bronchodilatory activities of Salmeterol.


penbutolol may decrease the bronchodilatory activities of aminophylline.


metoprolol may decrease the bronchodilatory activities of ritodrine.


atenolol may decrease the bronchodilatory activities of Salbutamol.


BOPINDOLOL may decrease the bronchodilatory activities of dyphylline.


metoprolol may decrease the bronchodilatory activities of ARBUTAMINE.


timolol may decrease the bronchodilatory activities of PROCATEROL.


CARTEOLOL may decrease the bronchodilatory activities of theophylline.


betaxolol may decrease the bronchodilatory activities of phenylpropanolamine.


ESMOLOL may decrease the bronchodilatory activities of Salbutamol.


ESMOLOL may decrease the bronchodilatory activities of PROCATEROL.


BOPINDOLOL may decrease the bronchodilatory activities of isoetharine.


CARTEOLOL may decrease the bronchodilatory activities of Salbutamol.


CARTEOLOL may decrease the bronchodilatory activities of PROCATEROL.


betaxolol may decrease the bronchodilatory activities of PIRBUTEROL.


BISOPROLOL may decrease the bronchodilatory activities of aminophylline.


timolol may decrease the bronchodilatory activities of isoproterenol.


acebutolol may decrease the bronchodilatory activities of metaproterenol.


BOPINDOLOL may decrease the bronchodilatory activities of phenylpropanolamine.


BUPRANOLOL may decrease the bronchodilatory activities of ARBUTAMINE.


Nebivolol may decrease the bronchodilatory activities of Arformoterol.


ESMOLOL may decrease the bronchodilatory activities of Vilanterol.


ESMOLOL may decrease the bronchodilatory activities of OLODATEROL.


celiprolol may decrease the bronchodilatory activities of Vilanterol.


celiprolol may decrease the bronchodilatory activities of OLODATEROL.


BUPRANOLOL may decrease the bronchodilatory activities of metaproterenol.


atenolol may decrease the bronchodilatory activities of dobutamine.


acebutolol may decrease the bronchodilatory activities of phenylpropanolamine.


betaxolol may decrease the bronchodilatory activities of terbutaline.


Nebivolol may decrease the bronchodilatory activities of Salbutamol.


alprenolol may decrease the bronchodilatory activities of Indacaterol.


penbutolol may decrease the bronchodilatory activities of PROCATEROL.


celiprolol may decrease the bronchodilatory activities of Indacaterol.


celiprolol may decrease the bronchodilatory activities of isoetharine.


BOPINDOLOL may decrease the bronchodilatory activities of ritodrine.


metoprolol may decrease the bronchodilatory activities of PROCATEROL.


oxprenolol may decrease the bronchodilatory activities of terbutaline.


oxprenolol may decrease the bronchodilatory activities of Arformoterol.


alprenolol may decrease the bronchodilatory activities of OLODATEROL.


alprenolol may decrease the bronchodilatory activities of Vilanterol.


BUPRANOLOL may decrease the bronchodilatory activities of theophylline.


atenolol may decrease the bronchodilatory activities of Indacaterol.


metoprolol may decrease the bronchodilatory activities of isoproterenol.


Nebivolol may decrease the bronchodilatory activities of Vilanterol.


Nebivolol may decrease the bronchodilatory activities of OLODATEROL.


ESMOLOL may decrease the bronchodilatory activities of dobutamine.


BOPINDOLOL may decrease the bronchodilatory activities of metaproterenol.


penbutolol may decrease the bronchodilatory activities of dobutamine.


alprenolol may decrease the bronchodilatory activities of Levalbuterol.


CARTEOLOL may decrease the bronchodilatory activities of dobutamine.


penbutolol may decrease the bronchodilatory activities of Indacaterol.


metoprolol may decrease the bronchodilatory activities of clenbuterol.


celiprolol may decrease the bronchodilatory activities of ritodrine.


penbutolol may decrease the bronchodilatory activities of Salbutamol.


BOPINDOLOL may decrease the bronchodilatory activities of isoproterenol.


acebutolol may decrease the bronchodilatory activities of formoterol.


acebutolol may decrease the bronchodilatory activities of ARBUTAMINE.


betaxolol may decrease the bronchodilatory activities of OLODATEROL.


BOPINDOLOL may decrease the bronchodilatory activities of ARBUTAMINE.


oxprenolol may decrease the bronchodilatory activities of Vilanterol.


timolol may decrease the bronchodilatory activities of ARBUTAMINE.


ESMOLOL may decrease the bronchodilatory activities of celiprolol.


metoprolol may decrease the bronchodilatory activities of phenylpropanolamine.


CARTEOLOL may decrease the bronchodilatory activities of Vilanterol.


CARTEOLOL may decrease the bronchodilatory activities of OLODATEROL.


BOPINDOLOL may decrease the bronchodilatory activities of PROCATEROL.


BISOPROLOL may decrease the bronchodilatory activities of Arformoterol.


BOPINDOLOL may decrease the bronchodilatory activities of clenbuterol.


Nebivolol may decrease the bronchodilatory activities of Salmeterol.


BOPINDOLOL may decrease the bronchodilatory activities of Bambuterol.


betaxolol may decrease the bronchodilatory activities of isoetharine.


timolol may decrease the bronchodilatory activities of metaproterenol.


Nebivolol may decrease the bronchodilatory activities of Indacaterol.


oxprenolol may decrease the bronchodilatory activities of isoetharine.


celiprolol may decrease the bronchodilatory activities of dyphylline.


acebutolol may decrease the bronchodilatory activities of PIRBUTEROL.


BISOPROLOL may decrease the bronchodilatory activities of Salmeterol.


celiprolol may decrease the bronchodilatory activities of isoproterenol.


betaxolol may decrease the bronchodilatory activities of isoproterenol.


BISOPROLOL may decrease the bronchodilatory activities of Salbutamol.


betaxolol may decrease the bronchodilatory activities of ARBUTAMINE.


BOPINDOLOL may decrease the bronchodilatory activities of Levalbuterol.


betaxolol may decrease the bronchodilatory activities of Vilanterol.


alprenolol may decrease the bronchodilatory activities of phenylpropanolamine.


timolol may decrease the bronchodilatory activities of phenylpropanolamine.


acebutolol may decrease the bronchodilatory activities of Vilanterol.


acebutolol may decrease the bronchodilatory activities of OLODATEROL.


acebutolol may decrease the bronchodilatory activities of Levalbuterol.


atenolol may decrease the bronchodilatory activities of celiprolol.


acebutolol may decrease the bronchodilatory activities of celiprolol.


celiprolol may decrease the bronchodilatory activities of theophylline.


betaxolol may decrease the bronchodilatory activities of dyphylline.


Nebivolol may decrease the bronchodilatory activities of Levalbuterol.


ESMOLOL may decrease the bronchodilatory activities of Levalbuterol.


metoprolol may decrease the bronchodilatory activities of terbutaline.


BOPINDOLOL may decrease the bronchodilatory activities of aminophylline.


alprenolol may decrease the bronchodilatory activities of Salbutamol.


BISOPROLOL may decrease the bronchodilatory activities of dobutamine.


oxprenolol may decrease the bronchodilatory activities of OLODATEROL.


ESMOLOL may decrease the bronchodilatory activities of metaproterenol.


penbutolol may decrease the bronchodilatory activities of metaproterenol.


betaxolol may decrease the bronchodilatory activities of Levalbuterol.


CARTEOLOL may decrease the bronchodilatory activities of metaproterenol.


penbutolol may decrease the bronchodilatory activities of phenylpropanolamine.


alprenolol may decrease the bronchodilatory activities of dyphylline.


BUPRANOLOL may decrease the bronchodilatory activities of PIRBUTEROL.


acebutolol may decrease the bronchodilatory activities of ritodrine.


ESMOLOL may decrease the bronchodilatory activities of ARBUTAMINE.


metoprolol may decrease the bronchodilatory activities of celiprolol.


Nebivolol may decrease the bronchodilatory activities of dobutamine.


CARTEOLOL may decrease the bronchodilatory activities of ARBUTAMINE.


cyclophosphamide may increase the cardiotoxic activities of Romidepsin.


cyclophosphamide may increase the cardiotoxic activities of Iobenguane.


cyclophosphamide may increase the cardiotoxic activities of tibolone.


cyclophosphamide may increase the cardiotoxic activities of pipobroman.


cyclophosphamide may increase the cardiotoxic activities of 5-Fluorouracil.


cyclophosphamide may increase the cardiotoxic activities of Idelalisib.


cyclophosphamide may increase the cardiotoxic activities of gemcitabine.


cyclophosphamide may increase the cardiotoxic activities of teniposide.


cyclophosphamide may increase the cardiotoxic activities of Epirubicin.


cyclophosphamide may increase the cardiotoxic activities of topotecan.


cyclophosphamide may increase the cardiotoxic activities of dexamethasone.


cyclophosphamide may increase the cardiotoxic activities of 6-Mercaptopurine.


cyclophosphamide may increase the cardiotoxic activities of IMIQUIMOD.


cyclophosphamide may increase the cardiotoxic activities of Alitretinoin.


cyclophosphamide may increase the cardiotoxic activities of anastrozole.


cyclophosphamide may increase the cardiotoxic activities of Amrubicin.


cyclophosphamide may increase the cardiotoxic activities of 5-Aminolevulinic acid.


cyclophosphamide may increase the cardiotoxic activities of oxaliplatin.


cyclophosphamide may increase the cardiotoxic activities of Clofarabine.


cyclophosphamide may increase the cardiotoxic activities of Venetoclax.


cyclophosphamide may increase the cardiotoxic activities of prednisone.


cyclophosphamide may increase the cardiotoxic activities of bicalutamide.


cyclophosphamide may increase the cardiotoxic activities of methyltestosterone.


cyclophosphamide may increase the cardiotoxic activities of Imatinib.


cyclophosphamide may increase the cardiotoxic activities of docetaxel.


cyclophosphamide may increase the cardiotoxic activities of melphalan.


cyclophosphamide may increase the cardiotoxic activities of hydroxyurea.


cyclophosphamide may increase the cardiotoxic activities of HYDROXYPROGESTERONE CAPROATE.


cyclophosphamide may increase the cardiotoxic activities of letrozole.


cyclophosphamide may increase the cardiotoxic activities of mitomycin C.


cyclophosphamide may increase the cardiotoxic activities of Bexarotene.


cyclophosphamide may increase the cardiotoxic activities of toremifene.


cyclophosphamide may increase the cardiotoxic activities of vindesine.


cyclophosphamide may increase the cardiotoxic activities of ciprofloxacin.


cyclophosphamide may increase the cardiotoxic activities of busulfan.


cyclophosphamide may increase the cardiotoxic activities of Erlotinib.


cyclophosphamide may increase the cardiotoxic activities of Decitabine.


cyclophosphamide may increase the cardiotoxic activities of trimetrexate.


cyclophosphamide may increase the cardiotoxic activities of Trifluridine.


cyclophosphamide may increase the cardiotoxic activities of Gemifloxacin.


cyclophosphamide may increase the cardiotoxic activities of Dexrazoxane.


cyclophosphamide may increase the cardiotoxic activities of Valrubicin.


cyclophosphamide may increase the cardiotoxic activities of 5-azacytidine.


cyclophosphamide may increase the cardiotoxic activities of flutamide.


cyclophosphamide may increase the cardiotoxic activities of dacarbazine.


cyclophosphamide may increase the cardiotoxic activities of Pixantrone.


cyclophosphamide may increase the cardiotoxic activities of Niraparib.


cyclophosphamide may increase the cardiotoxic activities of Vismodegib.


cyclophosphamide may increase the cardiotoxic activities of Vandetanib.


cyclophosphamide may increase the cardiotoxic activities of Gefitinib.


cyclophosphamide may increase the cardiotoxic activities of Nilotinib.


cyclophosphamide may increase the cardiotoxic activities of Miltefosine.


cyclophosphamide may increase the cardiotoxic activities of diethylstilbestrol.


cyclophosphamide may increase the cardiotoxic activities of azelaic acid.


cyclophosphamide may increase the cardiotoxic activities of goserelin.


cyclophosphamide may increase the cardiotoxic activities of vincristine.


cyclophosphamide may increase the cardiotoxic activities of Dasatinib.


cyclophosphamide may increase the cardiotoxic activities of homoharringtonine.


cyclophosphamide may increase the cardiotoxic activities of osimertinib.


cyclophosphamide may increase the cardiotoxic activities of fleroxacin.


cyclophosphamide may increase the cardiotoxic activities of Vorinostat.


cyclophosphamide may increase the cardiotoxic activities of streptozocin.


cyclophosphamide may increase the cardiotoxic activities of Sorafenib.


cyclophosphamide may increase the cardiotoxic activities of RUCAPARIB.


cyclophosphamide may increase the cardiotoxic activities of Pefloxacin.


cyclophosphamide may increase the cardiotoxic activities of Lenalidomide.


cyclophosphamide may increase the cardiotoxic activities of testolactone.


cyclophosphamide may increase the cardiotoxic activities of MEDROGESTONE.


cyclophosphamide may increase the cardiotoxic activities of Vinflunine.


cyclophosphamide may increase the cardiotoxic activities of carboplatin.


cyclophosphamide may increase the cardiotoxic activities of Dienogest.


cyclophosphamide may increase the cardiotoxic activities of altretamine.


cyclophosphamide may increase the cardiotoxic activities of methylprednisolone.


cyclophosphamide may increase the cardiotoxic activities of Regorafenib.


cyclophosphamide may increase the cardiotoxic activities of Pralatrexate.


cyclophosphamide may increase the cardiotoxic activities of plicamycin.


cyclophosphamide may increase the cardiotoxic activities of vinorelbine.


cyclophosphamide may increase the cardiotoxic activities of 4-PHENYLBUTYRIC ACID.


cyclophosphamide may increase the cardiotoxic activities of Ibrutinib.


cyclophosphamide may increase the cardiotoxic activities of podophyllotoxin.


cyclophosphamide may increase the cardiotoxic activities of methotrexate.


cyclophosphamide may increase the cardiotoxic activities of Cladribine.


cyclophosphamide may increase the cardiotoxic activities of Pirlindole.


cyclophosphamide may increase the cardiotoxic activities of IDARUBICIN.


cyclophosphamide may increase the cardiotoxic activities of amsacrine.


cyclophosphamide may increase the cardiotoxic activities of cabergoline.


cyclophosphamide may increase the cardiotoxic activities of Sunitinib.


cyclophosphamide may increase the cardiotoxic activities of Pemetrexed.


cyclophosphamide may increase the cardiotoxic activities of mebendazole.


cyclophosphamide may increase the cardiotoxic activities of Uramustine.


cyclophosphamide may increase the cardiotoxic activities of cinoxacin.


cyclophosphamide may increase the cardiotoxic activities of Pazopanib.


cyclophosphamide may increase the cardiotoxic activities of Fulvestrant.


cyclophosphamide may increase the cardiotoxic activities of mechlorethamine.


cyclophosphamide may increase the cardiotoxic activities of Olaparib.


cyclophosphamide may increase the cardiotoxic activities of Axitinib.


cyclophosphamide may increase the cardiotoxic activities of Nelarabine.


cyclophosphamide may increase the cardiotoxic activities of resveratrol.


cyclophosphamide may increase the cardiotoxic activities of TEMOPORFIN.


cyclophosphamide may increase the cardiotoxic activities of thiotepa.


cyclophosphamide may increase the cardiotoxic activities of Trabectedin.


cyclophosphamide may increase the cardiotoxic activities of procarbazine.


cyclophosphamide may increase the cardiotoxic activities of arsenic trioxide.


cyclophosphamide may increase the cardiotoxic activities of tegafur.


cyclophosphamide may increase the cardiotoxic activities of Ixabepilone.


cyclophosphamide may increase the cardiotoxic activities of tamoxifen.


cyclophosphamide may increase the cardiotoxic activities of ofloxacin.


cyclophosphamide may increase the cardiotoxic activities of irinotecan.


cyclophosphamide may increase the cardiotoxic activities of Fludarabine.


cyclophosphamide may increase the cardiotoxic activities of Masoprocol.


cyclophosphamide may increase the cardiotoxic activities of rapamycin.


pentostatin may increase the cardiotoxic activities of cyclophosphamide.


cyclophosphamide may increase the cardiotoxic activities of Midostaurin.


cyclophosphamide may increase the cardiotoxic activities of Ruxolitinib.


cyclophosphamide may increase the cardiotoxic activities of Cabozantinib.


cyclophosphamide may increase the cardiotoxic activities of Erismodegib.


cyclophosphamide may increase the cardiotoxic activities of Eribulin.


cyclophosphamide may increase the cardiotoxic activities of Bortezomib.


cyclophosphamide may increase the cardiotoxic activities of PHENYLACETIC ACID.


cyclophosphamide may increase the cardiotoxic activities of carmustine.


cyclophosphamide may increase the cardiotoxic activities of anagrelide.


cyclophosphamide may increase the cardiotoxic activities of estramustine.


cyclophosphamide may increase the cardiotoxic activities of vinblastine.


cyclophosphamide may increase the cardiotoxic activities of Carfilzomib.


cyclophosphamide may increase the cardiotoxic activities of nilutamide.


cyclophosphamide may increase the cardiotoxic activities of thalidomide.


cyclophosphamide may increase the cardiotoxic activities of lomustine.


cyclophosphamide may increase the cardiotoxic activities of moxifloxacin.


cyclophosphamide may increase the cardiotoxic activities of Gatifloxacin.


cyclophosphamide may increase the cardiotoxic activities of Octreotide.


cyclophosphamide may increase the cardiotoxic activities of LYCOPENE.


cyclophosphamide may increase the cardiotoxic activities of Calcipotriol.


cyclophosphamide may increase the cardiotoxic activities of nalidixic acid.


cyclophosphamide may increase the cardiotoxic activities of CYPROTERONE ACETATE.


cyclophosphamide may increase the cardiotoxic activities of sparfloxacin.


cyclophosphamide may increase the cardiotoxic activities of Bendamustine.


cyclophosphamide may increase the cardiotoxic activities of PONATINIB.


cyclophosphamide may increase the cardiotoxic activities of tretinoin.


cyclophosphamide may increase the cardiotoxic activities of formestane.


cyclophosphamide may increase the cardiotoxic activities of Crizotinib.


cyclophosphamide may increase the cardiotoxic activities of TRIPTORELIN.


cyclophosphamide may increase the cardiotoxic activities of Vapreotide.


cyclophosphamide may increase the cardiotoxic activities of thioguanine.


cyclophosphamide may increase the cardiotoxic activities of MEGESTROL ACETATE.


cyclophosphamide may increase the cardiotoxic activities of cytarabine.


cyclophosphamide may increase the cardiotoxic activities of aminoglutethimide.


cyclophosphamide may increase the cardiotoxic activities of etoposide.


cyclophosphamide may increase the cardiotoxic activities of daunorubicin.


cyclophosphamide may increase the cardiotoxic activities of Lenvatinib.


cyclophosphamide may increase the cardiotoxic activities of Nintedanib.


cyclophosphamide may increase the cardiotoxic activities of norfloxacin.


cyclophosphamide may increase the cardiotoxic activities of VERTEPORFIN.


cyclophosphamide may increase the cardiotoxic activities of Degarelix.


cyclophosphamide may increase the cardiotoxic activities of enoxacin.


cyclophosphamide may increase the cardiotoxic activities of Raltitrexed.


cyclophosphamide may increase the cardiotoxic activities of chlorambucil.


cyclophosphamide may increase the cardiotoxic activities of bleomycin.


cyclophosphamide may increase the cardiotoxic activities of Trilostane.


cyclophosphamide may increase the cardiotoxic activities of lomefloxacin.


cyclophosphamide may increase the cardiotoxic activities of suramin.


cyclophosphamide may increase the cardiotoxic activities of Lapatinib.


cyclophosphamide may increase the cardiotoxic activities of Nedaplatin.


cyclophosphamide may increase the cardiotoxic activities of Bosutinib.


cyclophosphamide may increase the cardiotoxic activities of CAPECITABINE.


cyclophosphamide may increase the cardiotoxic activities of actinomycin D.


cyclophosphamide may increase the cardiotoxic activities of quinacrine.


cyclophosphamide may increase the cardiotoxic activities of Pomalidomide.


cyclophosphamide may increase the cardiotoxic activities of Trametinib.


cyclophosphamide may increase the cardiotoxic activities of temozolomide.


cyclophosphamide may increase the cardiotoxic activities of Radium-223 chloride.


cyclophosphamide may increase the cardiotoxic activities of CABAZITAXEL.


cyclophosphamide may increase the cardiotoxic activities of Besifloxacin.


cyclophosphamide may increase the cardiotoxic activities of Gallium nitrate.


cyclophosphamide may increase the cardiotoxic activities of Ecabet.


cyclophosphamide may increase the cardiotoxic activities of EXEMESTANE.


cyclophosphamide may increase the cardiotoxic activities of Temsirolimus.


cyclophosphamide may increase the cardiotoxic activities of Methyl aminolevulinate.


cyclophosphamide may increase the cardiotoxic activities of 4-Methoxyphenol.


cyclophosphamide may increase the cardiotoxic activities of doxorubicin.


cyclophosphamide may increase the cardiotoxic activities of ifosfamide.


cyclophosphamide may increase the cardiotoxic activities of Trovafloxacin.


cyclophosphamide may increase the cardiotoxic activities of retinol.


cyclophosphamide may increase the cardiotoxic activities of floxuridine.


cyclophosphamide may increase the cardiotoxic activities of PIRFENIDONE.


cyclophosphamide may increase the cardiotoxic activities of Belinostat.


cyclophosphamide may increase the cardiotoxic activities of mycophenolate mofetil.


cyclophosphamide may increase the cardiotoxic activities of mycophenolic acid.


cyclophosphamide may increase the cardiotoxic activities of cisplatin.


cyclophosphamide may increase the cardiotoxic activities of PAMIDRONIC ACID.


cyclophosphamide may increase the cardiotoxic activities of Lanreotide.


cyclophosphamide may increase the cardiotoxic activities of sulindac.


cyclophosphamide may increase the cardiotoxic activities of mitoxantrone.


cyclophosphamide may increase the cardiotoxic activities of albendazole.


cyclophosphamide may increase the cardiotoxic activities of LEVOFLOXACIN.


cyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.


reserpine may increase the central nervous system depressant (CNS depressant) activities of doxylamine.


butorphanol may increase the central nervous system depressant (CNS depressant) activities of doxylamine.


proparacaine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.


thalidomide may increase the central nervous system depressant (CNS depressant) activities of VORTIOXETINE.


prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.


thalidomide may increase the central nervous system depressant (CNS depressant) activities of chloral hydrate.


thalidomide may increase the central nervous system depressant (CNS depressant) activities of 4-Hydroxybutanoic acid.


Suvorexant may increase the central nervous system depressant (CNS depressant) activities of BREXPIPRAZOLE.


ethanol may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.


methadone may increase the central nervous system depressant (CNS depressant) activities of flumazenil.


zolpidem may increase the central nervous system depressant (CNS depressant) activities of butalbital.


zolpidem may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.


Levomepromazine may increase the central nervous system depressant (CNS depressant) activities of brotizolam.


thalidomide may increase the central nervous system depressant (CNS depressant) activities of butorphanol.


buprenorphine may increase the central nervous system depressant (CNS depressant) activities of methoxyflurane.


orphenadrine may increase the central nervous system depressant (CNS depressant) activities of METAXALONE.


fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Dronabinol.